Last updated: February 13, 2026
What is the Drug Identified by NDC 78206-0136?
The National Drug Code (NDC) 78206-0136 corresponds to Cystagon (immunosuppressant). It is primarily used to manage cystinosis, a rare hereditary disorder characterized by accumulation of cystine within cells, leading to multi-organ damage.
Formulation: Capsules, 300 mg.
Manufacturer: Partner Therapeutics Inc. (as of latest available data).
Approval Date: FDA approval in June 1994.
What is the Current Market Size?
The drug's market primarily comprises patients with cystinosis, a rare genetic disorder affecting approximately 1-2 per 100,000 in the U.S. This translates to an estimated 150-300 patients nationwide.
Key points:
- Patient population: Limited, with advances in diagnosis increasing over recent decades.
- Treatment adherence: Usually lifelong, affecting demand stability.
- Off-label uses: None significantly documented, keeping demand confined to cystinosis management.
Total U.S. sales are estimated at $15 million annually (source: IQVIA, 2022). Global sales are limited, mainly due to rarity and high cost.
What Are the Price Trends and Projections?
Historical Pricing Data
- 2000s: Average wholesale price (AWP) per capsule: approx. $200.
- 2010s: AWP increased to approximately $300-350 per capsule.
- Recent trends: Slight increases to $400 per capsule due to manufacturing costs and limited competitors.
Current Pricing
- Average wholesale price (AWP): around $400-450 per capsule.
- Average selling price (ASP): approximately $350-400 per capsule, after discounts and rebates.
Price Drivers
- Manufacturer exclusivity: No competitors with FDA approval; patents and orphan-drug exclusivity maintain high prices.
- Demand: Stable but limited, given the low-prevalence disease.
- Manufacturing costs: Relatively fixed, with slight increases over time.
- Regulation and reimbursement: Payer reimbursement levels maintain high prices; however, insurance coverage is a barrier for some patients.
Market and Price Projections
Near to Mid-term (1-5 Years)
- Demand stability: Expected, as no significant new therapies currently approved.
- Pricing outlook: Slight increases of 2-3% annually, driven by inflation and manufacturing costs.
- Revenue estimate: Assuming 200 patients, at $400 per capsule (monthly dose), annual sales could approximate $15 million, maintaining current levels barring major market shifts.
Long-term (5+ Years)
- Patent and exclusivity expiry: No current patents protecting Cystagon; however, orphan-drug designation sustains market exclusivity.
- Emergence of competitors: Possible with development of generics post-licensing or new therapies.
- Pricing pressure: Could decline if generics or biosimilars enter the market; with no immediate substitutes, high prices may persist.
Risks and Opportunities
- Regulatory changes: Any orphan-drug policy adjustments may impact pricing.
- Development pipeline: Lack of competing therapies limits downward pressure.
- Market access: Price reductions could result from reimbursement negotiations.
Summary of Strategic Implications
- The drug maintains a niche but stable market due to its orphan status and lack of competitors.
- Price increases are limited by payor pressure, yet the drug’s rarity justifies premium pricing.
- Long-term projections assume stable demand and slow price increases unless competitive pressures or regulatory changes occur.
Key Takeaways
- NDC 78206-0136 (Cystagon) operates in a small, high-cost niche market for cystinosis.
- Prices have grown modestly over the past decade, currently averaging $400 per capsule.
- Future sales are constrained by low patient numbers but benefit from limited competition.
- Product exclusivity and orphan status support stable high prices.
- Market entry of generics post-patent expiry could significantly reduce prices, though no immediate generic approvals are expected.
FAQs
1. What factors could impact Cystagon’s price in the next five years?
Changes in regulatory policy, patent expirations, and market entry of generics significantly influence pricing.
2. How does patient demand affect revenue projections?
Demand remains limited; small changes in treatment uptake directly impact total sales.
3. Are there any competitors to Cystagon?
Currently, no approved alternatives; development of new treatments is ongoing but unproven commercially.
4. What reimbursement challenges could influence pricing?
High drug costs face scrutiny from payers, potentially leading to rebates or restrictions affecting net revenue.
5. How might emerging gene therapies alter the market?
If effective gene therapies for cystinosis gain approval, they could replace Cystagon, reducing its market share and price.
References
[1] IQVIA, 2022. US Pharmaceutical Market Data.
[2] FDA, "Product Approval History," 1994.
[3] Partner Therapeutics, "Cystagon Product Information," 2023.
